AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14533122 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT (Electroconvulsive Therapy)
Number of subjects: 121
Study 11031332 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS; 400 microg, twice daily)
Number of subjects: 407
Study 11031332 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray (twice daily)
Number of subjects: 407
Study 9238581 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational data from routine hospital statistics
Number of subjects: 0
Study 9238581 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustments to minimize bias and confounding
Number of subjects: 0
Study 1468091 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefadroxil monohydrate (30 mg/kg QD or 15 mg/kg BID)
Number of subjects: 1646
Study 3740024 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol electrolyte gut lavage solution (old, n=105)
Number of subjects: 557
Study 3740024 — intervention group
Group type: COMPARATOR
Intervention: Standard prep (old, n=71)
Number of subjects: 557
Study 29393079 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous ethanol injection (sterile 90% ethanol)
Number of subjects: 60
Study 29393079 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sterile normal saline)
Number of subjects: 60
Study 27447737 — intervention group
Group type: COMPARATOR
Intervention: Standard of care group
Number of subjects: 123
Study 27447737 — intervention group
Group type: COMPARATOR
Intervention: Standard of care + adherence electronic monitoring group
Number of subjects: 123
Study 27447737 — intervention group
Group type: COMPARATOR
Intervention: Integrated care group
Number of subjects: 123
Study 27447737 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence
Number of subjects: 123
Study 27447737 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline VASP-PRI
Number of subjects: 123
Study 24796048 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy group (acupuncture, moxibustion, and modified Mojie tablet)
Number of subjects: 120
Study 24796048 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture‐moxibustion group
Number of subjects: 120
Study 24796048 — intervention group
Group type: COMPARATOR
Intervention: Western medication group (gestrinone 2.5 mg, once a day, twice a week)
Number of subjects: 120
Study 24796048 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy group
Number of subjects: 120
Study 24796048 — intervention group
Group type: COMPARATOR
Intervention: Western medication group
Number of subjects: 120
Study 24796048 — intervention group
Group type: EXPERIMENTAL
Intervention: Other groups (acupuncture‐moxibustion and combined therapy)
Number of subjects: 120
Study 21934156 — intervention group
Group type: EXPERIMENTAL
Intervention: Yamax SW-200 pedometer worn over 365 consecutive days
Number of subjects: 23
Study 21934156 — intervention group
Group type: EXPERIMENTAL
Intervention: Data collection targeting certain months (e.g., May)
Number of subjects: 23
Study 20543522 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus pravastatin
Number of subjects: 0
Study 18215613 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (ACE inhibitor)
Number of subjects: 0
Study 18647523 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 8 grams daily
Number of subjects: 75
Study 18647523 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutathione (GSH) 1.2 grams daily
Number of subjects: 75
Study 15511725 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored messages
Number of subjects: 1776
Study 15511725 — intervention group
Group type: COMPARATOR
Intervention: Control messages
Number of subjects: 1776
Study 11164155 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of neoadjuvant hormonal treatment (NHT)
Number of subjects: 431
Study 11164155 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months of neoadjuvant hormonal treatment (NHT)
Number of subjects: 431
Study 11164155 — intervention group
Group type: COMPARATOR
Intervention: Immediate surgery
Number of subjects: 431
Study 9200377 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual regimen (omeprazole 0.6 mg/kg twice a day + amoxicillin 30 mg/kg twice a day)
Number of subjects: 22
Study 9200377 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple regimen (dual regimen + clarithromycin 15 mg/kg twice a day)
Number of subjects: 22
Study 9200377 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful H pylori eradication
Number of subjects: 22
Study 9200377 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ulcers treatment
Number of subjects: 22
Study 9200377 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects
Number of subjects: 22
Study 8477407 — intervention group
Group type: EXPERIMENTAL
Intervention: apomorphine injection (first and second injections)
Number of subjects: 10
Study 8477407 — intervention group
Group type: EXPERIMENTAL
Intervention: apomorphine injection (second injection administered 10 or 80 min after first)
Number of subjects: 10
Study 8477407 — intervention group
Group type: EXPERIMENTAL
Intervention: apomorphine injection (second administration)
Number of subjects: 10
Study 3630589 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg kg‐1 diazepam orally with 100 ml of water 2 h before surgery (Group 100)
Number of subjects: 40
Study 3630589 — intervention group
Group type: COMPARATOR
Intervention: 0.3 mg kg‐1 diazepam with 50 ml of water 2 h before surgery (Group 50)
Number of subjects: 40
Study 30519803 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First (HF) intervention
Number of subjects: 0
Study 30519803 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions aimed at preventing chronic homelessness, strengthening social networks and community involvement, and providing case management services
Number of subjects: 0
Study 28431849 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% improved hydrogen peroxide (IHP) disinfectant
Number of subjects: 4
Study 28431849 — intervention group
Group type: COMPARATOR
Intervention: Quaternary ammonium-based (Quat) disinfectant
Number of subjects: 4
Study 25851421 — intervention group
Group type: EXPERIMENTAL
Intervention: HG broccoli diet (400 g per week for 12 weeks)
Number of subjects: 130
Study 25851421 — intervention group
Group type: COMPARATOR
Intervention: Standard broccoli diet (400 g per week for 12 weeks)
Number of subjects: 130
Study 25851421 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined data from both studies for HG broccoli
Number of subjects: 130
Study 23689176 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervilenz® cervicometer
Number of subjects: 50
Study 23689176 — intervention group
Group type: COMPARATOR
Intervention: Transvaginal ultrasound
Number of subjects: 50
Study 21114369 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (40 mg oral dose)
Number of subjects: 13
Study 21114369 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin E1 (PGE1, alprostadil 200 ng · kg(‐1) · min(‐1) intravenous infusion)
Number of subjects: 13
Study 19683591 — intervention group
Group type: EXPERIMENTAL
Intervention: SFC+LTRA (pranlukast 450 mg daily)
Number of subjects: 32
Study 19683591 — intervention group
Group type: COMPARATOR
Intervention: SFC therapy alone
Number of subjects: 32
Study 16934430 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 22
Study 16934430 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin
Number of subjects: 22
Study 16934430 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone/sulbactam
Number of subjects: 22
Study 16934430 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 22
Study 15223852 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg flutamide once daily
Number of subjects: 50
Study 15223852 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg flutamide twice daily
Number of subjects: 50
Study 15223852 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg flutamide 3 times daily
Number of subjects: 50
Study 15223852 — intervention group
Group type: COMPARATOR
Intervention: Flutamide at 500 mg daily
Number of subjects: 50
Study 11422007 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril 20 mg single dose
Number of subjects: 6
Study 11422007 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinaprilat
Number of subjects: 6
Study 9639751 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025 mg ethinyl estradiol (EE)
Number of subjects: 19
Study 9639751 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg ethinyl estradiol (EE)
Number of subjects: 19
Study 8481662 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytosine arabinoside (3.0 g/m2 for < 60 years; 1.0 g/m2 for older pts.) combined with mitoxantrone (10 mg/m2/d)
Number of subjects: 193
Study 8481662 — intervention group
Group type: COMPARATOR
Intervention: Intermediate dose cytosine arabinoside (1.0 g/m2 for < 60 years; 0.5 g/m2 for older pts.) combined with mitoxantrone (10 mg/m2/d)
Number of subjects: 193
Study 8481662 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytosine arabinoside
Number of subjects: 193
Study 8481662 — intervention group
Group type: COMPARATOR
Intervention: Intermediate dose cytosine arabinoside
Number of subjects: 193
Study 8481662 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 193
Study 3318444 — intervention group
Group type: EXPERIMENTAL
Intervention: S-adenosylmethionine (SAMe) 1,200 mg
Number of subjects: 36
Study 3318444 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 150 mg
Number of subjects: 36
Study 3318444 — intervention group
Group type: EXPERIMENTAL
Intervention: S-adenosylmethionine (SAMe)
Number of subjects: 36
Study 3318444 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 36
Study 31619350 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration therapy (VT)
Number of subjects: 14
Study 31619350 — intervention group
Group type: COMPARATOR
Intervention: Control (no vibration therapy)
Number of subjects: 14
Study 30033595 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg once or twice daily
Number of subjects: 99
Study 30033595 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 99
Study 26869246 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy
Number of subjects: 1700
Study 26869246 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 1700
Study 24598243 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 (1.2 pmol/kg/min)
Number of subjects: 10
Study 24598243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 23072079 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (conventional acupuncture at Tianshu, Zusanli, Shangjuxu, Sanyinjiao, Taichong with electric stimulation at bilateral Tianshu), 3-4 treatments per week for 4 weeks.
Number of subjects: 70
Study 23072079 — intervention group
Group type: COMPARATOR
Intervention: Western medication (Pinaverium, 50 mg orally, 3 times a day for 4 weeks).
Number of subjects: 70
Study 20589921 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg)
Number of subjects: 17
Study 20589921 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (4 mg)
Number of subjects: 17
Study 20589921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 18408565 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg)
Number of subjects: 11
Study 18408565 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin (4 mg)
Number of subjects: 11
Study 18408565 — intervention group
Group type: EXPERIMENTAL
Intervention: SLCO1B1*15 variant
Number of subjects: 11
Study 16088834 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 days of artesunate-atovaquone-proguanil (AAP)
Number of subjects: 81
Study 16088834 — intervention group
Group type: COMPARATOR
Intervention: 7 days of supervised quinine (SQ7)
Number of subjects: 81
Study 11115818 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal infusion of lipid
Number of subjects: 29
Study 11115818 — intervention group
Group type: COMPARATOR
Intervention: Duodenal infusion of saline
Number of subjects: 29
Study 9695140 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (1.0 mg/kg)
Number of subjects: 10
Study 9695140 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 10
Study 7981009 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol 5 mg (N5)
Number of subjects: 8
Study 7981009 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol 20 mg (N20)
Number of subjects: 8
Study 7981009 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol 80 mg (N80)
Number of subjects: 8
Study 7981009 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 8
Study 2723129 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 3
Study 2723129 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate
Number of subjects: 3
Study 2723129 — intervention group
Group type: COMPARATOR
Intervention: Fenfluramine
Number of subjects: 3
Study 29386337 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT) as an add-on to standard PR programme
Number of subjects: 84
Study 29386337 — intervention group
Group type: COMPARATOR
Intervention: Standard PR programme alone
Number of subjects: 84
Study 27356696 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education programs for teachers and support for tobacco control policy implementation
Number of subjects: 72
Study 27356696 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 72
Study 24937652 — intervention group
Group type: EXPERIMENTAL
Intervention: Watch video group (43 patients, 43 eyes)
Number of subjects: 86
Study 24937652 — intervention group
Group type: COMPARATOR
Intervention: Orally taught health education group (43 patients, 43 eyes)
Number of subjects: 86
Study 23106948 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib or sunitinib
Number of subjects: 124
Study 23106948 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 124
Study 20920812 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable Priority Training (VPT)
Number of subjects: 0
Study 20920812 — intervention group
Group type: COMPARATOR
Intervention: Full Emphasis Training (FET)
Number of subjects: 0
Study 18410636 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetanus toxoid booster (TTB) immunization, administered to 52 participants (15 from PI-sparing, 37 from PI-containing) at median 25 weeks after HAART initiation.
Number of subjects: 75
Study 18410636 — intervention group
Group type: COMPARATOR
Intervention: No TTB immunization, administered to 23 participants (6 from PI-sparing, 17 from PI-containing).
Number of subjects: 75
Study 18410636 — intervention group
Group type: EXPERIMENTAL
Intervention: PI-sparing regimen, 21 participants.
Number of subjects: 75
Study 18410636 — intervention group
Group type: COMPARATOR
Intervention: PI-containing regimen, 54 participants.
Number of subjects: 75
Study 15813871 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 15
Study 15813871 — intervention group
Group type: COMPARATOR
Intervention: Prone position
Number of subjects: 15
Study 12204508 — intervention group
Group type: EXPERIMENTAL
Intervention: felodipine (5 mg)
Number of subjects: 145
Study 12204508 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol (50 mg)
Number of subjects: 145
Study 12204508 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril (10 mg)
Number of subjects: 145
Study 12204508 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 145
Study 12204508 — intervention group
Group type: EXPERIMENTAL
Intervention: clinically prescribed medications
Number of subjects: 145
Study 11151867 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (40 mg once daily), amoxicillin (1 g b.i.d.), and clarithromycin (500 mg b.i.d.) (EAC)
Number of subjects: 612
Study 11151867 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole (40 mg once daily), clarithromycin (500 mg twice daily) (EC)
Number of subjects: 612
Study 11151867 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole (40 mg once daily) (E)
Number of subjects: 612
Study 11151867 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline clarithromycin resistance
Number of subjects: 612
Study 11151867 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergent resistance after treatment with EAC
Number of subjects: 612
Study 8807099 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion GM‐CSF (GM‐CSF (CI))
Number of subjects: 0
Study 8807099 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion GM‐CSF followed by sequential G‐CSF (GM‐CSF/G‐CSF)
Number of subjects: 0
Study 8807099 — intervention group
Group type: COMPARATOR
Intervention: Historical control patients receiving GM‐CSF as a 2‐h intravenous infusion (GM‐CSF (2‐h))
Number of subjects: 0
Study 8807099 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion GM‐CSF (GM‐CSF (CI)) and GM‐CSF/G‐CSF
Number of subjects: 0
Study 1581405 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM-CSF at a daily dose of 108 micrograms (group I)
Number of subjects: 82
Study 1581405 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM-CSF at a daily dose of 216 micrograms (group II)
Number of subjects: 82
Study 1581405 — intervention group
Group type: COMPARATOR
Intervention: Cytogenetic analysis
Number of subjects: 82
Study 1581405 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response to GM-CSF
Number of subjects: 82
Study 1581405 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion of treatment
Number of subjects: 82
Study 3970886 — intervention group
Group type: EXPERIMENTAL
Intervention: Steamed flax dust
Number of subjects: 12
Study 3970886 — intervention group
Group type: COMPARATOR
Intervention: Untreated flax dust
Number of subjects: 12
Study 31152476 — intervention group
Group type: EXPERIMENTAL
Intervention: everolimus (EVR) with reduced-exposure calcineurin inhibitor (EVR + rCNI)
Number of subjects: 2037
Study 31152476 — intervention group
Group type: COMPARATOR
Intervention: mycophenolate with standard-exposure CNI
Number of subjects: 2037
Study 27645834 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-I (Cognitive Behavior Therapy for Insomnia)
Number of subjects: 112
Study 27645834 — intervention group
Group type: COMPARATOR
Intervention: WL (Wait-list)
Number of subjects: 112
Study 26882041 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure-lowering therapy in patients with preserved LVEF (>55%)
Number of subjects: 1849
Study 26882041 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure-lowering therapy in patients with intermediate LVEF (45-55%)
Number of subjects: 1849
Study 26882041 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure-lowering therapy in patients with reduced LVEF (<45%)
Number of subjects: 1849
Study 25424952 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administered qHPV and HAV/HBV vaccine
Number of subjects: 416
Study 25424952 — intervention group
Group type: EXPERIMENTAL
Intervention: Separated doses of qHPV and HAV/HBV vaccine
Number of subjects: 416
Study 25424952 — intervention group
Group type: COMPARATOR
Intervention: Both groups post-second dose of qHPV and HAV/HBV
Number of subjects: 416
Study 22329385 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Start intervention (HV+)
Number of subjects: 0
Study 22329385 — intervention group
Group type: COMPARATOR
Intervention: Cognitive reframing intervention (HV)
Number of subjects: 0
Study 20080850 — intervention group
Group type: EXPERIMENTAL
Intervention: T(3) therapy (0.8 microg . kg(‐1) bolus; infusion 0.113 microg . kg(‐1) . h(‐1))
Number of subjects: 30
Study 20080850 — intervention group
Group type: EXPERIMENTAL
Intervention: T(3) therapy
Number of subjects: 30
Study 20080850 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5% dextrose)
Number of subjects: 30
Study 17631211 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP
Number of subjects: 3761
Study 17631211 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 3761
Study 17631211 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibition
Number of subjects: 3761
Study 15290000 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 80 mg QD
Number of subjects: 30
Study 15290000 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg BID
Number of subjects: 30
Study 15290000 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine 50 mg BID
Number of subjects: 30
Study 15290000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11710819 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 3 mg plus dexamethasone 10 mg
Number of subjects: 40
Study 11710819 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 8 mg plus dexamethasone 10 mg
Number of subjects: 40
Study 9164214 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic fluorouracil (5FU)/folinic acid
Number of subjects: 135
Study 9164214 — intervention group
Group type: COMPARATOR
Intervention: Symptom control
Number of subjects: 135
Study 9164214 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic arterial floxuridine (FUDR)
Number of subjects: 135
Study 9164214 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy
Number of subjects: 135
Study 9164214 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic arterial chemotherapy (HAI)
Number of subjects: 135
Study 7967418 — intervention group
Group type: EXPERIMENTAL
Intervention: NHL-BFM 90 therapy
Number of subjects: 346
Study 3111821 — intervention group
Group type: EXPERIMENTAL
Intervention: Paedmin
Number of subjects: 0
Study 3111821 — intervention group
Group type: COMPARATOR
Intervention: Vamin
Number of subjects: 0
Study 3111821 — intervention group
Group type: EXPERIMENTAL
Intervention: Both nutrition groups
Number of subjects: 0
Study 1699654 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms/m2 per day of rhG-CSF
Number of subjects: 16
Study 1699654 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms/m2 per day of rhG-CSF
Number of subjects: 16
Study 1699654 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms/m2 per day of rhG-CSF
Number of subjects: 16
Study 1699654 — intervention group
Group type: EXPERIMENTAL
Intervention: More than 100 micrograms/m2 per day of rhG-CSF
Number of subjects: 16